Back to Research Home
ILMNIllumina Inc
Health Care · Medical Specialities · Large
$269.42+0.01%
As of 23 Oct 2026Mkt cap $32.2B
Stage 13
AVOID
Fundamentals
21.6/75
Technical
6.2/15
Independent
27.8/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- −1.6%
- 3M
- +42.2%
- 6M
- +110.7%
- 1Y
- +177.1%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 50.1xHist median 23.1x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 45.1x
- FCF yield
- 2.2%
Quality
- ROIC
- 26.6%
- Operating margin
- -19.1%
- FCF margin
- 21.4%
- Current ratio
- 2.1x
Growth
- Revenue growth
- −0.7%Latest FY YoY
- Revenue CAGR
- −1.0%
- EPS CAGR
- +2.0%
- FCF CAGR
- +28.9%
Capital
- Share-count trend
- −0.6%3Y annualised
- Net cash
- $355M-0.3x OCF
Annual trend
- CAGR 2021–2025
- −1.0%
- Latest · 2025
- $4B
- YoY
- −0.7%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded